The Use of Decellularized Lung Matrices for Airway Regeneration

Severe airway diseases, including tracheal stenosis, bronchial obstruction, and end-stage lung conditions, represent a significant clinical challenge. Traditional treatments often rely on transplantation, yet donor shortages and lifelong immunosuppression limit their applicability. Over the past decade, regenerative medicine has advanced a compelling alternative: decellularized lung matrices. By stripping a lung of its cellular content while preserving its natural extracellular matrix (ECM), researchers can create a biological scaffold that supports the growth of new, functional airway tissue. This approach merges the structural fidelity of native organs with the plasticity of cellular engineering, offering a path toward personalized airway repair without the drawbacks of synthetic grafts.

What Are Decellularized Lung Matrices?

A decellularized lung matrix is essentially a lung that has been chemically and enzymatically processed to remove all living cells, leaving behind the ECM. The ECM is a complex network of collagen, elastin, proteoglycans, and glycoproteins that provides structural support, biochemical signaling, and mechanical integrity to lung tissue. Crucially, the ECM retains the intricate three-dimensional architecture of the lung, including the branching airways, the microvascular network, and the alveolar sacs. This retained architecture is vital because it preserves the spatial cues needed for cells to organize into functional tissue. Unlike synthetic scaffolds, which often fail to replicate this micro- and macro-structure, decellularized matrices present a ready-made blueprint for regeneration. The resulting scaffold is acellular, sterile, and can be stored for later use. When recellularized with the appropriate cell types—such as airway epithelial cells, endothelial cells, or mesenchymal stem cells—these matrices can be transformed into living grafts that mimic native lung tissue.

The Decellularization Process: Step by Step

Decellularization is a carefully balanced procedure that must remove all cellular material without compromising the ECM. The process typically follows these stages:

  1. Harvesting and preparation – Lungs are obtained from cadaveric donors (human or animal) after ethical and institutional approvals. They are flushed with anticoagulants and preservation solutions to remove blood clots and prevent thrombosis.
  2. Perfusion with detergents – The lung is perfused through the pulmonary artery and trachea with agents such as sodium dodecyl sulfate (SDS), Triton X-100, and deoxycholate. These detergents lyse cell membranes and solubilize intracellular and nuclear contents. The perfusion flow rate, pressure, and duration are optimized to ensure even distribution while minimizing ECM damage.
  3. Washing – After detergent treatment, the scaffold is thoroughly washed with phosphate-buffered saline (PBS) to remove residual detergents and cellular debris. This step is critical because leftover detergents can be toxic to newly seeded cells.
  4. Enzymatic digestion (optional) – Some protocols include brief DNase/RNase treatments to break down residual nucleic acids, further reducing the risk of immune activation upon implantation.
  5. Sterilization – The final scaffold is sterilized using gamma irradiation, ethylene oxide, or peracetic acid. Care is taken to avoid denaturing the ECM proteins.
  6. Quality control – The decellularized matrix is assessed for DNA content (typically below 50 ng/mg dry weight), absence of visible nuclei, preservation of ECM proteins (collagen, elastin, laminin), and retention of structural integrity through mechanical testing and imaging (e.g., micro-CT, histology).

Different animal models—porcine, rodent, and non-human primates—are used to optimize these protocols. The choice of detergents and perfusion parameters directly affects the ECM composition. For example, SDS is aggressive and may remove glycosaminoglycans (GAGs) that are essential for cell signaling, while milder protocols using CHAPS or zwitterionic detergents better retain GAGs but may leave residual cellular material. Balancing these trade-offs is an active area of research.

Recellularization: Seeding Cells onto the Scaffold

Once a decellularized lung matrix is prepared, it must be recellularized to become a functional graft. Recellularization involves introducing cells into the scaffold and guiding them to populate the appropriate anatomical compartments. The most common cell sources include:

  • Autologous airway epithelial cells – Obtained via bronchial brushing or biopsy from the patient, expanded in culture, and then seeded. Using the patient’s own cells avoids immune rejection.
  • Induced pluripotent stem cells (iPSCs) – Differentiated into respiratory epithelial cells (ciliated, goblet, club, and basal cells) or alveolar type I/II pneumocytes. iPSCs offer nearly unlimited cell numbers but require rigorous differentiation protocols.
  • Mesenchymal stem cells (MSCs) – Derived from bone marrow, adipose tissue, or umbilical cord. MSCs provide paracrine support, modulate inflammation, and can differentiate into fibroblasts and smooth muscle cells.
  • Endothelial progenitor cells (EPCs) – Seeded into the vascular compartment to regenerate the microvasculature, essential for graft viability.

Seeding techniques include static incubation, dynamic seeding in bioreactors, and serial perfusion. Bioreactors are particularly valuable because they can mimic physiological airflow and perfusion, which promotes uniform cell distribution and maturation. For airway regeneration, attention is focused on seeding the tracheal or bronchial lumen with epithelial cells while the vascular side receives endothelial cells. After seeding, the construct is cultured for days to weeks to allow cells to attach, proliferate, and form confluent layers. Advanced bioreactors can apply cyclic mechanical stretch and fluid shear stress, which have been shown to improve epithelial barrier function and ciliation.

Applications in Airway Regeneration

The primary clinical target is the reconstruction of damaged airways, including the trachea, bronchi, and segmental bronchioles. Several scenarios are being explored in preclinical and early clinical settings:

Tracheal Replacement

Tracheal defects from trauma, tumor resection, or congenital stenosis often require segmental replacement. Decellularized human or porcine tracheal grafts have been implanted in patients with promising short-term results. For example, Glasgow researchers reported the first successful use of a decellularized human trachea recellularized with the patient’s epithelial cells and MSCs. The graft remained patent and showed ciliary function at one year. However, long-term outcomes have been variable due to issues with graft collapse, stenosis, and inadequate revascularization.

Bronchial and Lobar Repairs

In patients with lung cancer requiring sleeve resection or lobectomy, decellularized matrices can serve as patches or staged grafts to replace resected bronchial segments. Animal studies in pigs show that decellularized bronchial scaffolds seeded with autologous epithelial cells integrate into the host airway and restore mucociliary clearance within months. Clinical translation is ongoing at specialized centers.

Peripheral Lung Reconstruction

For diffuse damage—such as in emphysema or pulmonary fibrosis—whole-lung decellularization and recellularization is being explored as a bridge or alternative to transplantation. In preclinical models, recellularized rodent lungs have been orthotopically transplanted and supported gas exchange for short periods (hours to days). Scaling this to human-sized lungs remains a formidable challenge due to the need to regenerate the alveolar-capillary interface and the extensive vascular network.

Advantages of Decellularized Matrices

  • Preserved native architecture – The ECM maintains the complex branching hierarchy, providing optimal mechanical support and spatial guidance for cell organization.
  • Biocompatibility – Decellularized matrices are essentially the patient’s own extracellular framework (if from a human donor) or a xenograft that can be rendered non-immunogenic by cellular removal.
  • Reduced immune response – By removing donor cells, the primary antigenic stimuli are eliminated. Although residual ECM proteins can still trigger mild immune reactions, they are generally well tolerated, especially when the scaffold is recellularized with autologous cells.
  • Mechanical strength – The ECM retains tensile strength and elasticity comparable to native lung, preventing collapse and maintaining patency during breathing.
  • Promotes cell attachment and function – The ECM contains adhesion ligands (e.g., fibronectin, laminin) and growth factors (e.g., VEGF, TGF-β) that support cell survival, differentiation, and migration.

Challenges and Current Limitations

Despite promising foundational work, several barriers must be overcome before decellularized lung matrices become a standard therapy.

Complete Recellularization

Seeding cells into a dense, three-dimensional scaffold is not trivial. Cells often fail to reach the entire depth of the matrix, leaving regions acellular. In the airway, the epithelium must be confluent to provide a barrier; gaps can lead to infection and scarring. Achieving uniform distribution across the full length of a human-sized trachea or bronchus remains an engineering obstacle. Bioreactors with pulsatile perfusion and negative-pressure ventilation show promise but are not yet optimized for clinical grade production.

Vascularization

A decellularized lung matrix retains its vascular conduits, but those conduits must be re-endothelialized to prevent thrombosis and provide oxygen to deeper tissues. Without a functional capillary bed, the graft will only survive if it is very thin (e.g., a tracheal patch) or relies on diffusion from surrounding host tissue. For larger segments, angiogenesis from the host must invade the graft. Prevascularization strategies—such as co-seeding endothelial cells with MSCs or using angiogenic growth factors—are being investigated, but sustained perfusion remains elusive.

Long-Term Stability

Implanted grafts face mechanical stress from breathing, coughing, and positional changes. ECM scaffolds can undergo remodeling, potentially leading to degradation, stenosis, or metaplasia. Some animal studies have reported cartilage-like deposition in subepithelial layers, causing stiffness. Long-term monitoring in large animal models (sheep, pigs) is ongoing to assess patency, infection rates, and functional durability.

Regulatory and Manufacturing Hurdles

Decellularized matrices derived from human tissues are regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps) in the United States, or as advanced therapy medicinal products (ATMPs) in Europe. This requires meticulous donor screening, standardized processing, and batch consistency. Establishing quality assurance for a biological scaffold is more complex than for a synthetic device. Variability between donor lungs (age, disease state, preservation) directly affects ECM composition and performance. Scalable, reproducible manufacturing protocols are still under development.

Future Directions and Emerging Research

To address these challenges, researchers are exploring several cutting-edge approaches:

Customized ECM Decellularization Protocols

Rather than a one-size-fits-all approach, decellularization protocols may be tailored to the region of the airway being repaired. For example, a protocol for tracheal cartilage might use milder detergents to preserve GAGs, while a protocol for the bronchial epithelium might prioritize retention of basement membrane components. Advanced analytical methods—such as proteomics and biomechanical testing—can guide protocol optimization.

Hybrid Scaffolds

Combining decellularized ECM with synthetic polymers (e.g., PCL, PEG) can enhance mechanical strength and allow controlled release of growth factors. Electrospun nanofiber layers can be incorporated to reinforce weak areas like the tracheal cartilage defects. Hybrid scaffolds also enable the inclusion of bio-orthogonal chemistry for attaching cell-adhesive peptides.

In Situ Recellularization

Rather than culturing a graft in a bioreactor, some teams are exploring implantation of a decellularized matrix supplemented with chemoattractants that recruit host cells in vivo. This "cell-free" approach could simplify manufacturing and regulatory approval. Early studies in tracheal defects show that a decellularized porcine patch soaked with stromal cell-derived factor-1 (SDF-1) attracts circulating progenitor cells, resulting in re-epithelialization within weeks.

Organoid and 3D Bioprinting Integration

Lung organoids derived from iPSCs can be microdissected and seeded into specific niches of the decellularized matrix. Similarly, 3D bioprinting can deposit patient-specific cells and hydrogels into the scaffold to repair localized defects—for example, printing airway epithelial cells over a denuded bronchial segment. Combining these technologies may enable creation of patient-specific airway grafts with complex cellular heterogeneity.

Clinical Translation Efforts

Several clinical trials are underway or in planning. The European Union-funded "RegenerAir" consortium is testing a decellularized human tracheal scaffold (HitAir) in a phase I/II trial for patients with long-segment tracheal stenosis. In the United States, the FDA has granted orphan drug designation for a decellularized pediatric tracheal graft. Meanwhile, researchers at Harvard, University of Pittsburgh, and University Medical Center Utrecht are refining whole-lung decellularization for eventual transplantation in end-stage lung disease, with initial proof-of-concept studies in non-human primates.

Conclusion

Decellularized lung matrices represent a powerful platform for airway regeneration, combining the structural perfection of nature’s scaffold with the versatility of modern cell engineering. While challenges in recellularization, vascularization, and long-term stability persist, the pace of innovation is accelerating. With continued advances in bioreactor design, stem cell biology, and regulatory science, decellularized matrices are poised to move from the laboratory into the operating room, offering patients with damaged airways a biologically authentic solution. The future of lung regeneration is not about replacing a lung—it is about rebuilding it from the inside out.

For further reading, see these external resources: